Sagent Pharmaceuticals Inc (SGNT) 21.56 $SGNT
Why Sagent Pharmaceuticals Inc. Shares Jumped
Sean Williams, The Motley Fool - Motley Fool - Tue May 06, 1:03PM CDT
Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis. What: Shares of Sagent Pharmaceuticals , a specialty...
Sagent Pharmaceuticals Reports First Quarter 2014 Financial Results
GlobeNewswire - Tue May 06, 6:05AM CDT
Sagent Pharmaceuticals, Inc. (Nasdaq:SGNT), a leader of specialty pharmaceutical products with a specific emphasis on the injectable market, today announced financial results for the quarter ended March 31, 2014.
Should You Buy Sagent Pharmaceuticals (SGNT) Ahead of Earnings? - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Fri May 02, 7:30AM CDT
Sagent Pharmaceuticals has been witnessing a significant price rise in the past month with a positive momentum in the earnings estimate front
Sagent Pharmaceuticals Sets Date and Time for Release of First Quarter 2014 Financial Results
GlobeNewswire - Wed Apr 23, 7:00AM CDT
Sagent Pharmaceuticals, Inc. (Nasdaq:SGNT), a leader of specialty pharmaceutical products with an emphasis on the injectable market, today announced that it will release financial results for the 2014 first quarter pre-market on Tuesday, May 6, 2014 and will host a teleconference and webcast at 9 a.m. ET to review the results.
Sagent Pharmaceuticals announces relaunch of Adenosine Injection, USP
M2 - Tue Apr 22, 7:04AM CDT
Pharmaceutical company Sagent Pharmaceuticals (NasdaqGS:SGNT) said on Monday that it has re introduced its Adenosine Injection, USP in improved prefilled plastic syringes.
Sagent Pharmaceuticals Announces the Reintroduction of Adenosine Injection, USP
GlobeNewswire - Mon Apr 21, 7:10AM CDT
Sagent Pharmaceuticals, Inc. (Nasdaq:SGNT) today announced the reintroduction of Adenosine Injection, USP, an antiarrhythmic agent, now in improved prefilled plastic syringes. According to IMS, for the 12 months ending February 2014, the US market for Adenosine Injection, USP approximated $28 million. As with all products in Sagent's portfolio, Adenosine features Sagent's PreventIV Measures packaging and labeling, designed to help reduce medication errors.
Sagent Pharmaceuticals reports market availibility of Adenosine Injection, USP
M2 - Tue Apr 01, 6:37AM CDT
Pharmaceutical company Sagent Pharmaceuticals Inc (NasdaqGS:SGNT) stated on Monday that it has introduced Adenosine Injection, USP, in two preservative- free vial presentations.
Sagent Pharmaceuticals and the Chicago Innovation Awards to Ring NASDAQ
GlobeNewswire - Mon Mar 31, 7:12AM CDT
Sagent Pharmaceuticals, Inc. (Nasdaq:SGNT) will join the Chicago Innovation Awards, the Chicago region's foremost annual celebration of innovation, in New York City on Monday, March 31, to close the NASDAQ Stock Market, the premier exchange for technology companies. The event, arranged by the Chicago Innovation Awards, will emphasize the surge of innovation that is occurring in the Chicago region and shine a spotlight on the organizations that make up its vibrant economy.
Sagent Pharmaceuticals Announces the Launch of Adenosine Injection, USP
GlobeNewswire - Mon Mar 31, 7:12AM CDT
Sagent Pharmaceuticals, Inc. (Nasdaq:SGNT) today announced the launch of Adenosine Injection, USP, a pharmacologic stress agent, in two preservative- free vial presentations. According to IMS, for the 12 months ending January 2014, the US market for Adenosine Injection, USP approximated $43 million. As with all products in Sagent's portfolio, Adenosine features the company's PreventIV Measures packaging and labeling, designed to help reduce medication errors.
Sagent Pharmaceuticals Initiates a Nationwide Voluntary Recall of Two Lots of Zoledronic Acid Injection, 5mg/100mL due to Potential Lack of Container Integrity
GlobeNewswire - Tue Mar 04, 11:04AM CST
Sagent Pharmaceuticals, Inc. (Nasdaq:SGNT) today announced the voluntary nationwide recall of two lots of Zoledronic Acid Injection, 5mg/100mL premix bag (NDC number 25021-830-82) distributed by Sagent. Sagent has initiated this voluntary recall of Zoledronic Acid Injection, 5mg/100mL to the user level due to the discovery of four (4) leaking premix bags detected during an investigation conducted in response to a product complaint. The subject bags were not administered to patients as the leakage was readily apparent.
Sagent Pharmaceuticals Reports Fourth Quarter and Full Year 2013 Results
GlobeNewswire - Tue Feb 11, 6:00AM CST
Sagent Pharmaceuticals, Inc. (Nasdaq:SGNT), a leader of specialty pharmaceutical products with a specific emphasis on the injectable market, today announced financial results for the fourth quarter and fiscal year ended December 31, 2013.
Pentagon Awards $1.23 Billion in Defense Contracts Tuesday
Rich Smith, The Motley Fool - Motley Fool - Tue Feb 04, 5:30PM CST
The Department of Defense awarded only seven defense contracts Tuesday, yet still managed to hand out $1.23 billion worth of work. More than half the funds awarded went to a single recipient, privately held government contractor KS International...
Sagent Pharmaceuticals opens National Research Centre in Chengdu, China
M2 - Tue Feb 04, 6:10AM CST
US-based specialist pharmaceutical company Sagent Pharmaceuticals Inc (NasdaqGS:SGNT) reported on Monday the opening of its National Research Centre (NRC) in China.
Sagent Pharmaceuticals Launches National Research Center in Chengdu, China
GlobeNewswire - Mon Feb 03, 7:00AM CST
Sagent Pharmaceuticals, Inc. (Nasdaq:SGNT), a leader of specialty pharmaceutical products with a specific emphasis on the injectable market, today announced the launch of its National Research Center ("NRC"
in Chengdu, China. Based in Chengdu's Bio-Technology Park, the NRC will focus on process and method development of technically challenging specialty injectable pharmaceuticals.
Sagent Pharmaceuticals Sets Date and Time for Release of Fourth Quarter and Full Year 2013 Financial Results
GlobeNewswire - Thu Jan 30, 3:30PM CST
Sagent Pharmaceuticals, Inc. (Nasdaq:SGNT), a leader of specialty pharmaceutical products with an emphasis on the injectable market, today announced that it will release financial results for the 2013 fourth quarter and fiscal year end pre-market on Tuesday, February 11, 2014 and will host a teleconference and webcast at 9 a.m. ET to review the results.
Regulus (RGLS) Jumps: Stock Rises 5.6% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Fri Jan 17, 8:46AM CST
Regulus was a big mover last session, with shares rising nearly 6%.
Sucampo (SCMP) Worth Watching: Stock Rises 11.9% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Tue Jan 14, 8:25AM CST
Sucampo Pharmaceuticals was a big mover last session, with shares rising nearly 12%.
IGI, Laboratories (IG) Soars: Stock Adds 10.4% in Session - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Tue Jan 14, 7:57AM CST
IGI, Laboratories, Inc. (IG) was a big mover last session, as the company saw its shares rise over 10% on the day.
Tesaro (TSRO) Jumps: Stock Moves 8.1% Higher - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Mon Jan 13, 8:46AM CST
Tesaro was a big mover last session, with shares rising above 8%.
Flamel Technologies (FLML) in Focus: Stock Jumps 8.6% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Mon Jan 13, 7:37AM CST
Flamel Technologies SA was a big mover last session, as the company saw its shares rise almost 9% on the day.
Why Sagent Pharmaceuticals Inc. Shares Jumped
Sean Williams, The Motley Fool - Motley Fool - Tue May 06, 1:03PM CDT
Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis. What: Shares of Sagent Pharmaceuticals , a specialty...
Sagent Pharmaceuticals Reports First Quarter 2014 Financial Results
GlobeNewswire - Tue May 06, 6:05AM CDT
Sagent Pharmaceuticals, Inc. (Nasdaq:SGNT), a leader of specialty pharmaceutical products with a specific emphasis on the injectable market, today announced financial results for the quarter ended March 31, 2014.
Should You Buy Sagent Pharmaceuticals (SGNT) Ahead of Earnings? - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Fri May 02, 7:30AM CDT
Sagent Pharmaceuticals has been witnessing a significant price rise in the past month with a positive momentum in the earnings estimate front
Sagent Pharmaceuticals Sets Date and Time for Release of First Quarter 2014 Financial Results
GlobeNewswire - Wed Apr 23, 7:00AM CDT
Sagent Pharmaceuticals, Inc. (Nasdaq:SGNT), a leader of specialty pharmaceutical products with an emphasis on the injectable market, today announced that it will release financial results for the 2014 first quarter pre-market on Tuesday, May 6, 2014 and will host a teleconference and webcast at 9 a.m. ET to review the results.
Sagent Pharmaceuticals announces relaunch of Adenosine Injection, USP
M2 - Tue Apr 22, 7:04AM CDT
Pharmaceutical company Sagent Pharmaceuticals (NasdaqGS:SGNT) said on Monday that it has re introduced its Adenosine Injection, USP in improved prefilled plastic syringes.
Sagent Pharmaceuticals Announces the Reintroduction of Adenosine Injection, USP
GlobeNewswire - Mon Apr 21, 7:10AM CDT
Sagent Pharmaceuticals, Inc. (Nasdaq:SGNT) today announced the reintroduction of Adenosine Injection, USP, an antiarrhythmic agent, now in improved prefilled plastic syringes. According to IMS, for the 12 months ending February 2014, the US market for Adenosine Injection, USP approximated $28 million. As with all products in Sagent's portfolio, Adenosine features Sagent's PreventIV Measures packaging and labeling, designed to help reduce medication errors.
Sagent Pharmaceuticals reports market availibility of Adenosine Injection, USP
M2 - Tue Apr 01, 6:37AM CDT
Pharmaceutical company Sagent Pharmaceuticals Inc (NasdaqGS:SGNT) stated on Monday that it has introduced Adenosine Injection, USP, in two preservative- free vial presentations.
Sagent Pharmaceuticals and the Chicago Innovation Awards to Ring NASDAQ
GlobeNewswire - Mon Mar 31, 7:12AM CDT
Sagent Pharmaceuticals, Inc. (Nasdaq:SGNT) will join the Chicago Innovation Awards, the Chicago region's foremost annual celebration of innovation, in New York City on Monday, March 31, to close the NASDAQ Stock Market, the premier exchange for technology companies. The event, arranged by the Chicago Innovation Awards, will emphasize the surge of innovation that is occurring in the Chicago region and shine a spotlight on the organizations that make up its vibrant economy.
Sagent Pharmaceuticals Announces the Launch of Adenosine Injection, USP
GlobeNewswire - Mon Mar 31, 7:12AM CDT
Sagent Pharmaceuticals, Inc. (Nasdaq:SGNT) today announced the launch of Adenosine Injection, USP, a pharmacologic stress agent, in two preservative- free vial presentations. According to IMS, for the 12 months ending January 2014, the US market for Adenosine Injection, USP approximated $43 million. As with all products in Sagent's portfolio, Adenosine features the company's PreventIV Measures packaging and labeling, designed to help reduce medication errors.
Sagent Pharmaceuticals Initiates a Nationwide Voluntary Recall of Two Lots of Zoledronic Acid Injection, 5mg/100mL due to Potential Lack of Container Integrity
GlobeNewswire - Tue Mar 04, 11:04AM CST
Sagent Pharmaceuticals, Inc. (Nasdaq:SGNT) today announced the voluntary nationwide recall of two lots of Zoledronic Acid Injection, 5mg/100mL premix bag (NDC number 25021-830-82) distributed by Sagent. Sagent has initiated this voluntary recall of Zoledronic Acid Injection, 5mg/100mL to the user level due to the discovery of four (4) leaking premix bags detected during an investigation conducted in response to a product complaint. The subject bags were not administered to patients as the leakage was readily apparent.
Sagent Pharmaceuticals Reports Fourth Quarter and Full Year 2013 Results
GlobeNewswire - Tue Feb 11, 6:00AM CST
Sagent Pharmaceuticals, Inc. (Nasdaq:SGNT), a leader of specialty pharmaceutical products with a specific emphasis on the injectable market, today announced financial results for the fourth quarter and fiscal year ended December 31, 2013.
Pentagon Awards $1.23 Billion in Defense Contracts Tuesday
Rich Smith, The Motley Fool - Motley Fool - Tue Feb 04, 5:30PM CST
The Department of Defense awarded only seven defense contracts Tuesday, yet still managed to hand out $1.23 billion worth of work. More than half the funds awarded went to a single recipient, privately held government contractor KS International...
Sagent Pharmaceuticals opens National Research Centre in Chengdu, China
M2 - Tue Feb 04, 6:10AM CST
US-based specialist pharmaceutical company Sagent Pharmaceuticals Inc (NasdaqGS:SGNT) reported on Monday the opening of its National Research Centre (NRC) in China.
Sagent Pharmaceuticals Launches National Research Center in Chengdu, China
GlobeNewswire - Mon Feb 03, 7:00AM CST
Sagent Pharmaceuticals, Inc. (Nasdaq:SGNT), a leader of specialty pharmaceutical products with a specific emphasis on the injectable market, today announced the launch of its National Research Center ("NRC"
in Chengdu, China. Based in Chengdu's Bio-Technology Park, the NRC will focus on process and method development of technically challenging specialty injectable pharmaceuticals. Sagent Pharmaceuticals Sets Date and Time for Release of Fourth Quarter and Full Year 2013 Financial Results
GlobeNewswire - Thu Jan 30, 3:30PM CST
Sagent Pharmaceuticals, Inc. (Nasdaq:SGNT), a leader of specialty pharmaceutical products with an emphasis on the injectable market, today announced that it will release financial results for the 2013 fourth quarter and fiscal year end pre-market on Tuesday, February 11, 2014 and will host a teleconference and webcast at 9 a.m. ET to review the results.
Regulus (RGLS) Jumps: Stock Rises 5.6% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Fri Jan 17, 8:46AM CST
Regulus was a big mover last session, with shares rising nearly 6%.
Sucampo (SCMP) Worth Watching: Stock Rises 11.9% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Tue Jan 14, 8:25AM CST
Sucampo Pharmaceuticals was a big mover last session, with shares rising nearly 12%.
IGI, Laboratories (IG) Soars: Stock Adds 10.4% in Session - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Tue Jan 14, 7:57AM CST
IGI, Laboratories, Inc. (IG) was a big mover last session, as the company saw its shares rise over 10% on the day.
Tesaro (TSRO) Jumps: Stock Moves 8.1% Higher - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Mon Jan 13, 8:46AM CST
Tesaro was a big mover last session, with shares rising above 8%.
Flamel Technologies (FLML) in Focus: Stock Jumps 8.6% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Mon Jan 13, 7:37AM CST
Flamel Technologies SA was a big mover last session, as the company saw its shares rise almost 9% on the day.
